We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Johnson & Johnson to Acquire Cardiovascular Technology Company Abiomed in USD 16.6 Billion Deal

By HospiMedica International staff writers
Posted on 01 Nov 2022
Print article
Image: Johnson & Johnson’s acquisition of Abiomed will bring lifesaving innovations to more heart patients with unmet need (Photo courtesy of Johnson & Johnson)
Image: Johnson & Johnson’s acquisition of Abiomed will bring lifesaving innovations to more heart patients with unmet need (Photo courtesy of Johnson & Johnson)

Johnson & Johnson (New Brunswick, N.J., USA) has entered into a definitive agreement to acquire all outstanding shares of Abiomed, Inc. (Danvers, MA, USA) in a deal valued at approximately USD 16.6 billion which includes cash acquired. Abiomed’s shareholders will also receive a non-tradable contingent value right (CVR) entitling the holder to receive up to USD 35 per share in cash if certain commercial and clinical milestones are achieved. Following the completion of the transaction, Abiomed will operate as a standalone business within Johnson & Johnson MedTech (JJMT) and broaden its position as a growing cardiovascular innovator, advancing the standard of care in one of healthcare’s largest unmet need disease states: heart failure and recovery.

Abiomed is a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure, an extensive innovation pipeline of life-saving technologies, and an 18-year track record of profitable growth. Abiomed operates in one of the fastest growing medtech segments with significant expansion opportunities in indication, geography, and product. Johnson & Johnson’s footprint, leading capabilities in physician education, commercial excellence, and robust clinical expertise will complement Abiomed’s capabilities, accelerating access and adoption of these lifesaving technologies to more patients around the world.

Abiomed’s Impella heart pumps – a breakthrough technology with exclusive FDA approvals for patients with severe coronary artery disease requiring high-risk PCI (percutaneous coronary intervention), treatment of AMI (acute myocardial infarction) cardiogenic shock, or right heart failure – will complement JJMT’s portfolio, which includes the leading Biosense Webster electrophysiology business, and further accelerate JJMT’s shift into high-growth markets. The combination broadens Johnson & Johnson’s position as a cardiovascular innovator by adding a world-leading portfolio in heart recovery – with innovative R&D programs, exclusive FDA approvals, and multiple randomized controlled trials underway with the aim of achieving Class I clinical guidelines for Impella – to expand access to patient populations.

“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” said Joaquin Duato, Chief Executive Officer of Johnson & Johnson. “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”

“Abiomed’s skilled workforce and strong relationships with clinicians, along with its innovative cardiovascular portfolio and robust pipeline, complement our MedTech portfolio, global footprint and robust clinical expertise. Together, we have the incredible opportunity to bring lifesaving innovations to more patients around the world,” said Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson. “We are committed to investing for growth and look forward to welcoming the talented team and working together to foster our shared patient-first mindset and winning culture of innovation.”

“We are pleased to have reached an agreement that reflects the remarkable value Abiomed created with our revolutionary Impella heart pump platform and promising pipeline,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “This transaction partners us with an organization that shares our patients-first mindset and creates immediate value for our patients, customers, employees and shareholders. It will enable us to leverage Johnson & Johnson’s global scale, commercial strength and clinical expertise to accelerate our mission of making heart recovery the global standard of care.”

Related Links:
Johnson & Johnson
Abiomed, Inc.

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
HAI Assay Quality Control
Amplichek II
New
Sepsis Test
MM SEPSIS PANEL
New
Lyophilizer
FD150

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: PATHFAST is a compact immunoanalyzer with superior assay performance (Photo courtesy of PHC Europe)

Benchtop Immunoanalyzer Delivers Lab Quality Results for Cardiology, Intensive Care and Emergency Wards at POC

A compact immunoanalyzer with superior assay performance combines the accuracy of a full-scale lab analyzer with the flexibility of a mobile solution, making it an ideal analysis system for laboratories,... Read more

Surgical Techniques

view channel
Image: Bioelectric medicine could stem excessive blood loss (Photo courtesy of Pexels)

Wearable Neurostimulation Solution Could Stem Excessive Blood Loss in the OR

A wearable neurostimulation solution focused on lessening excessive blood loss could save precious time for surgical teams in the operating room. A collaboration between Spark Biomedical, Inc.... Read more

Patient Care

view channel
Image: The digital stretcher scales are designed specifically for emergent situations in hospitals and emergency rooms (Photo courtesy of DETECTO)

Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER

For emergency arrivals into a hospital, time is of the essence for gathering patient weights. Now, digital stretcher scales specifically designed for emergent situations in hospitals and emergency rooms... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.